Viking Holdings price target raised to $51 from $40 at BofA
BofA raised the firm’s price target on Viking Holdings (VIK) to $51 from $40 and keeps a Buy rating on the shares. For Q3, the firm notes ...
AstraZeneca: Strong Growth Potential And Market Volatility Offer Opportunity
AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...
Hosted on MSN9h
Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand?
Amgen stock rebounded Wednesday, shaking off "overdone" fears that ... Rival drugs from Eli Lilly and Viking Therapeutics also target GIPR, but they mimic it. Renza noted the placebo group had a ...
Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly?
So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...